|
Status |
Public on May 31, 2023 |
Title |
EZH2 inhibtion and IFNy treatment of patient derived organoids |
Organisms |
Homo sapiens; Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
37333199, 38265267 |
|
Submission date |
May 25, 2023 |
Last update date |
Feb 26, 2024 |
Contact name |
Jinpeng Liu |
Organization name |
Markey Cancer Center
|
Street address |
800 Rose St
|
City |
Lexington |
State/province |
Kentucky |
ZIP/Postal code |
40536 |
Country |
USA |
|
|
Platforms (5)
|
GPL21273 |
HiSeq X Ten (Mus musculus) |
GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
Samples (54)
|
|
This SuperSeries is composed of the following SubSeries: |
GSE233468 |
EZH2 inhibtion and IFNy treatment of patient derived organoids [RNA-seq] |
GSE233469 |
EZH2 inhibtion and IFNy treatment of patient derived organoids [ChIP-seq] |
GSE233665 |
EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq] |
|
Relations |
BioProject |
PRJNA976305 |